Table 1 High-dose regimens, stem cells, and purging

From: Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma

 

No. patients (%)

 

(N=49)

High-dose regimens

 BCV

18 (37)

 Melphalan/TBI

13 (27)

 Cyclophosphamide/TBI

12 (24)

 BEAM

3 (6)

 Mitoxantrone/melphalan

2 (4)

 Melphalan

1 (2)

 TBI-containing regimens

25 (51)

Stem-cell source and purging

 PBSC

32 (65)

 BM alone

10 (20)

4-HC purged

8

 PBSC and BM

7 (14)

4-HC purged

1

  1. BCV=BCNU 300 mg/m2 once i.v. on day −6, cyclophosphamide 1500 mg/m2 once daily i.v. on days −5 to −2 (total dose 6000 mg/m2), and etoposide 350 mg/m2 every 12 h i.v. on days −5 to −3 (total dose 2100 mg/m2).
  2. Melphalan/TBI=melphalan 140 mg/m2 once i.v. on day −4 and TBI at 200 cGy in two divided fractions daily on days −3 to −1 (total dose 1200 cGy).
  3. Cyclophosphamide/TBI=cyclophosphamide 60 mg/kg once daily i.v. on days −5 to −4 (total dose 120 mg/kg) and TBI at 200 cGy in two divided fractions daily on days −3 to −1 (total dose 1200 cGy).
  4. BEAM=BCNU 300 mg/m2 once i.v. on day −7, etoposide 200 mg/m2 once daily i.v. on days −6 to −3 (total dose 800 mg/m2), cytarabine 150 mg/m2 every 12 h i.v. on days −6 to −3 (total dose 1200 mg/m2), melphalan 140 mg/m2 once i.v. on day −2.
  5. Mitoxantrone/Melphalan=mitoxantrone 60 mg/m2 once i.v. on day −4, melphalan 180 mg/m2 once i.v. on day −1.
  6. Melphalan=melphalan 180 mg/m2 once i.v. on day −1.
  7. 4-HC=4-hydroxyperoxycyclophosphamide.
Back to article page